Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 3, 2026Antimicrobial Agents and ChemotherapyOpen Access

Analysis of interactions between posaconazole/voriconazole and venetoclax

View Full Paper
Ask AI
Bookmark
Share

Authors

CLChaoying LiuSinopec (China)XXXiaoyan XieNorthern Jiangsu People's HospitalMSMei SunNorthern Jiangsu People's Hospital

Discussion

Loading...

Member takes

Implication

Analysis investigates safety and blood concentration changes of venetoclax in myeloid malignancies when combined with triazole antifungals.

Key Points

  • This research explores how posaconazole and voriconazole affect the blood levels and safety of venetoclax in patients with myeloid neoplasms.
  • Enrolled patients with myeloid malignancies receiving venetoclax from April 2023 to 2025.
  • Divided into two groups: venetoclax alone and venetoclax with triazole antifungals.
  • Measured steady-state plasma concentrations of venetoclax using liquid chromatography-mass spectrometry.
  • Conducted statistical analyses using IBM SPSS Statistics 26.
  • Plasma concentrations of venetoclax were significantly higher in the combination therapy group compared to monotherapy (P < 0.001).
  • No significant difference in venetoclax concentrations between posaconazole and voriconazole combinations (P = 0.176).
  • No correlation between venetoclax concentration and triazole antifungal concentration was found.
  • No significant differences in the incidence of severe adverse events between the two groups.

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/69cf5f505a333a821460e640https://doi.org/10.1128/aac.01101-25
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes2024 · 43 citations
  2. 2Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)2025 · 59 citations
  3. 3Effect of Oral Posaconazole on Venetoclax Plasma Concentration and its Efficacy in Patients with Acute Myeloid Leukemia2025 · 2 citations
  4. 4Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)2023 · 98 citations
  5. 5Incidence and impact of invasive fungal infection comparing post-transplant cyclophosphamide with cyclosporine plus methotrexate GVHD prophylaxis in allogeneic HSCT2024 · 1 citations